<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375957</url>
  </required_header>
  <id_info>
    <org_study_id>ATx201-005</org_study_id>
    <nct_id>NCT03375957</nct_id>
  </id_info>
  <brief_title>Sensitization Study of ATx201 in Healthy Volunteers</brief_title>
  <official_title>A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AntibioTx A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AntibioTx A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-site study to evaluate the sensitization potential of topically
      applied ATx201 GEL, 2% and 4%, along with a placebo control, in healthy human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Actual">March 15, 2018</completion_date>
  <primary_completion_date type="Actual">February 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dermal Response Score</measure>
    <time_frame>21 days</time_frame>
    <description>number of patients with a dermal response score of at least 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermal Response and Effects Score</measure>
    <time_frame>21 days</time_frame>
    <description>number of patients with a dermal response and effects score of at least 3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Sensitivity, Contact</condition>
  <arm_group>
    <arm_group_label>ATx201 2% Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 4% Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 Gel Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx201</intervention_name>
    <description>two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms</description>
    <arm_group_label>ATx201 2% Gel</arm_group_label>
    <arm_group_label>ATx201 4% Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx201 Placebo Gel</intervention_name>
    <description>two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms</description>
    <arm_group_label>ATx201 Gel Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health

          -  Body Mass Index no less than 19.0 and no greater than 36.0 kg/m² (inclusive).

          -  Demonstrates a Fitzpatrick skin score of I - IV

          -  Female subjects must agree to use acceptable contraceptive methods from the Screening
             Visit through 90 days after the End of Study (EOS) Visit; or postmenopausal status
             with no menses for at least 1 year prior to the Screening Visit.

          -  Willing to refrain from excessive consumption of sodium in food or beverage 48 hours
             prior to Day 1 through EOS Visit.

          -  Willing to shower using the same non-medicated soap/cleansers, and abstain from
             excessive sun exposure (including tanning salons) from the Screening Visit through EOS
             Visit.

        Exclusion Criteria:

          -  Reports a history of diabetes mellitus, clinically significant asthma (acceptable if
             no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or
             circulatory disease.

          -  Reports use of any oral, nasal or topical corticosteroids, or oral or topical
             retinoids (other than Vitamin A at normal dietary amounts)

          -  Reports a significant history of allergy to soaps, lotions, emollients, ointments,
             creams, cosmetics, adhesives, or latex.

          -  Reports a history of significant skin conditions or disorders such as psoriasis,
             atopic dermatitis, etc.

          -  Reports a history of significant dermatologic cancers.

          -  Displays an obvious difference in skin color between upper arms or upper back or the
             presence of a skin anomaly

          -  Reports smoking or use of tobacco or nicotine delivery products within 14 days prior
             to Day 1 through EOS Visit.

          -  Presence of any clinically significant results from laboratory tests and vital signs
             assessments, as judged by the Investigator.

          -  A female who is pregnant, lactating, breastfeeding, or intends to become pregnant over
             the course of the study.

          -  Reports a history of drug or alcohol addiction or abuse within the past year.

          -  Reports having donated blood or plasma within 48 hours prior to Day 1 through EOS
             Visit.

          -  Subject exhibits excessive hair density on the upper arms or back such that patch
             adhesion could be compromised.

          -  Subject reports undergoing hair depilation (e.g. chemical, laser, physical) within 30
             days prior to Day 1 through EOS Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Prokocimer, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

